Track Categories
The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.
Dementia is not a specific disease. It's an overall term that describes a wide range of symptoms associated with a decline in memory or other thinking skills severe enough to reduce a person's ability to perform everyday activities. Alzheimer's disease. Vascular dementia, which occurs after a stroke, is the second most common dementia type. But there are many other conditions that can cause symptoms of dementia, including some that are reversible, such as thyroid problems and vitamin deficiencies. Dementia is a syndrome that involves severe loss of cognitive abilities as a result of disease or injury. Dementia caused by traumatic brain injury is often static, whereas dementia caused by neurodegenerative disorders, such as Alzheimer's disease, is usually progressive and can eventually be fatal. Dementia can be grouped based on the part of brain being affected. it is roughly true that the earliest symptoms in "cortical" dementia include difficulty with high-level behaviour’s such as memory, language, problem-solving and reasoning; these functions tend to be less impaired in "subcortical" dementia. Cortical dementia occurs because of damage in the cerebral cortex, the outer layer of the brain. They play a critical role in memory and language. The symptoms usually include severe memory loss. Alzheimer's and Creutzfeldt-Jakob disease are two forms of cortical dementia. Subcortical dementia occurs due to the damage to the part of the brain beneath the cortex. The person suffering from it can show changes in their speed of thinking. Usually, people with subcortical dementia don't have forgetfulness and language problems. Parkinson's disease, Huntington's disease, and HIV are two forms subcortical dementia.
- Track 1-1Mixed dementia
- Track 1-2Frontotemporal dementia
- Track 1-3Neurogenesis in dementia
- Track 1-4Global prevalence of dementia
- Track 1-5Signs and symptoms of dementia
- Track 1-6Primary mental health care and nursing
- Track 1-7Novel therapeutics technology
- Track 1-8Novel therapeutics strategies for Dementia
- Track 2-1Risk factor of vascular dementia
- Track 2-2Antipsychotic medications
- Track 2-3Palliative care in vascular dementia
- Track 2-4Autophagy
- Track 2-5Synucleinopathies
- Track 3-1Role of Plaques and Tangles
- Track 3-2Diagnostic and Statistical Manual of Mental Disorders
- Track 3-3Mental Diseases
- Track 3-4Dominantly Inherited Alzheimer Network (DIAN) study
- Track 3-5Causative Genetic Mutation
Parkinson's ailment (PD) is an unending and dynamic neurological disorders that influence engine work, causing bradykinesia, postural unsteadiness, inflexibility and tremor very still. Side effects grow progressively, making start finding troublesome. PD likewise has a few non-engine highlights, including psychological wellness issues, rest unsettling influences and autonomic aggravations. At introduce, there is no cure for PD. The treatment is, subsequently, gone from treating side effects. There are right now two fundamental ways to deal with enhanced dopaminergic action inside the mind: expanding dopamine emission with exogenous operators and focusing on related neurotransmission pathways. Levodopa is the regular metabolic antecedent of dopamine and is profoundly successful for treating PD indications. Side effects of Parkinson's Diseases are normally overseen utilizing a specific dopamine receptor agonist. While these medications are valuable in beginning time Parkinson's, they tend to lose viability in later sickness stages
- Track 4-1Prevention of Parkinson’s Disease by Immune gene
- Track 4-2Disease beyond Genetic Mutations
- Track 5-1Frontotemporal Dementia
- Track 5-2Subcortical vascular dementia
- Track 5-3Vascular Contributions to Cognitive Impairment and Dementia
- Track 5-4Post-stroke dementia
- Track 5-5Pathobiology of vascular dementia
Brain diseases come in different forms of Infections, trauma, stroke, seizures, and tumors are some of the major categories of brain diseases. Here's an overview of various diseases of the brain.
- Track 6-1Migraine
- Track 6-2Attention deficit hyperactivity disorder
- Track 6-3Motor neuron disease
- Track 6-4Bipolar disorder
- Track 6-5Arteriovenous malformation
- Track 6-6 Encephalitis
- Track 6-7Seizures
- Track 6-8Stoke
- Track 6-9Brain abscess
- Track 6-10Psychological Trauma
- Track 7-1Childhood Trauma and PTSD Symptoms
- Track 7-2Psychological Therapies
- Track 7-3Childhood trauma with cognitive function in healthy adults
- Track 7-4Post-traumatic stress disorder and Alzheimers disease
- Track 7-5Psychological Disorders
- Track 8-1Chronic Neurological Diseases
- Track 8-2Neurocutaneous Syndromes
- Track 8-3Epilepsy and Seizures
- Track 8-4Cerebral Aneurysm
- Track 8-5Muscular Dystrophy
- Track 9-1Alzheimeras disease
- Track 9-2 Huntingtons disease
- Track 9-3Amyotrophic lateral sclerosis (ALS)
- Track 9-4Motor neuron disease
- Track 9-5Prions
Vascular insults can start a course of Molecular event occasions prompting neurodegeneration, psychological disorders, and dementia. Here, the molecular mechanisms and cell in cerebral veins pathophysiological occasions prompting disturbance of the blood-cerebrum obstruction and cerebral blood stream dysregulation and the neurovascular unit, which all may add to the beginning and movement of dementia and Alzheimer's disease. From the most punctual phases of improvement, when cerebral neurogenesis and angiogenesis are weaved, to the finish of life, the interaction between neural frameworks and vascular of the cerebrum is basic in wellbeing and infection. Cerebral blood stream control is fundamental for ordinary mind work. The mammalian mind has developed an exceptional system for CBF control known as neurovascular coupling.
- Track 10-1Neurovascular pathways to neurodegeneration
- Track 10-2Neurovascular regulation in the normal brain
- Track 10-3Cerebral microvasculature
- Track 10-4Dysfunction of the blood brain barrier
- Track 10-5Neurovascular coupling
- Track 10-6Dermal Neurovascular Dysfunction
- Track 11-1Neurogenesis & Neuron Regeneration
- Track 11-2Structural Neuroimaging
- Track 11-3Neuropathology
- Track 11-4Cerebrospinal fluid biomarker
- Track 11-5Structural and functional biomarkers
Neuropharmacology is an extremely wide locale of science that includes numerous parts of the sensory system from single neuron control to whole ranges of the cerebrum, spinal line, and fringe nerves. To better comprehend the premise behind medication advancement, one should first see how neurons speak with each other. This article will concentrate on both behavioral and atomic neuropharmacology; the real receptors, particle channels, and neurotransmitters controlled through medication activity and how individuals with a neurological issue advantage from this medication activity.
- Track 12-1Neuroscience and neuropharmacology
- Track 12-2Neurochemical interaction
- Track 12-3Molecular neuropharmacology
- Track 12-4Behavioral neuropharmacology
- Track 12-5Advance research in neuropharmacology
- Track 13-1Dementia nursing care plan
- Track 13-2Music therapy in dementia
- Track 13-3Physiotherapy for dementia
- Track 13-4Clinical features of dementia
- Track 13-5Therapeutic interventions in dementia
Most continuous endeavors to battle Alzheimer Disease are centered around treating its clinical symptoms, however the neuropathologic changes fundamental show up decades sooner and turn out to be basically irreversible when the sickness achieves its clinical stages.This requires treating at preclinical stages, which requires a superior comprehension of the essential instruments prompting Alzheimer Disease pathology. Alzheimer's infection is a complex hereditary issue that is the main source of dementia in the elderly. Atomic confirmation raised the presumptions that trafficking of the amyloid precursor protein is under control of insulin flagging. Most progressing endeavors to battle Alzheimer infection are centered around treating its clinical side effects, however the neuropathologic changes fundamental show up decades sooner and turn out to be basically irreversible when the ailment achieves its clinical stages.
- Track 14-1Fixing Genetic risk for Alzheimers
- Track 14-2Medial Temporal Lobe
- Track 14-3Nervous System Disease
- Track 14-4Neurofibrillary Degeneration
- Track 15-1Amyloid Plaques
- Track 15-2Neurofibrillary Tangles
- Track 15-3Chronic Inflammation
- Track 15-4Vascular Contributions to Alzheimers Disease
- Track 15-5Loss of Neuronal Connections and Cell Death
- Track 15-6Diagnostic studies
- Track 16-1Targeting Amyloid
- Track 16-2Ramping Up the Immune System
- Track 16-3Non-Medication Approaches
- Track 16-4Treatment trials
Alzheimer's Disease as a dynamic and fatal neurodegenerative disease speaks to an immense neglected requirement for treatment. The low viability of current treatment techniques isn't just because of low medication intensity yet in addition because of the nearness of different hindrances in the conveyance courses. One of the fundamental boundaries is the blood brain boundary. The expanding predominance of Alzheimer's Diseases and the low viability of ebb and flow treatments have expanded the measure of research on unwinding of sickness pathways and advancement of treatment techniques. One of the fascinating regions for the last subject is biotechnology and their applications. Nanotechnology is a standout amongst the most vital field in biotechnology and has a noteworthy part in the improvement of novel remedial modalities with expanded adequacy. In the nanotechnology field, materials are designed with utilitarian association on the nanoscale. Every one of the materials are utilized for association and incitement of organic frameworks at the atomic level to instigate physiological reactions. One of the primary issues concerning the treatment of neurodegenerative diseases is identified with medicate conveyance.
- Track 17-1Alzheimer disease drug discovery
- Track 17-2Molecular and Cellular Basis of Neurodegeneration
- Track 17-3Vaccine against Alzheimers disease
- Track 17-4Biology of Ageing
- Track 18-1Diagnostic Alzheimer
- Track 18-2Neuropsychological testing
- Track 18-3Treatments for Behavior
- Track 18-4Biomarker Research
- Track 18-5Precision Medicine for Alzheimer Disease
- Track 19-1Molecular Genetics of Frontotemporal Dementia
- Track 19-2Molecular Genetics of Neurodegenerative Dementia
- Track 19-3Human stem cell models of dementia
- Track 19-4Fixing Genetic risk for Alzheimer’s
- Track 19-5Dealing with Dementia Behaviour
- Track 20-1Dementia Risk and Preventions
- Track 21-1Novel therapeutics strategies for Dementia
- Track 21-2Novel therapeutics technology
- Track 21-3Novel therapeutics molecule
- Track 21-4Anti-dementia drugs
- Track 21-5Novel drug target for the treatment of dementia
- Track 22-1Spine Cancer and Spine Cancer Treatment
- Track 22-2Glioblastoma
- Track 22-3Meningioma
- Track 22-4Brain Stem Tumors
- Track 22-5Malignant Brain Cancers and Brain Metastasis
- Track 22-6Pediatric Neuro Oncology
- Track 22-7Astrocytoma
- Track 22-8Neurotoxicity
- Track 22-9Risk Factors
- Track 22-10Radiation Therapy And Chemotherapy